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SUMMARY
p38a is a stress-activated protein kinase that negatively regulates malignant transformation induced
by oncogenic H-Ras, although themechanisms involved are not fully understood. Here, we show that
p38a is not a general inhibitor of oncogenic signaling, but that it specifically modulates transfor-
mation induced by oncogenes that produce reactive oxygen species (ROS). This inhibitory effect
is due to the ROS-induced activation of p38a early in the process of transformation, which induces
apoptosis and prevents the accumulation of ROS and their carcinogenic effects. Accordingly, highly
tumorigenic cancer cell lines have developed a mechanism to uncouple p38a activation from ROS
production. Our results indicate that oxidative stress sensing plays a key role in the inhibition of
tumor initiation by p38a.INTRODUCTION
Cancer is a complex disease that involves the disruption
of cell and tissue homeostasis via a series of successive
genetic changes (Hanahan and Weinberg, 2000). These
include activating mutations in the H-, N-, and K-ras
proto-oncogene family members, which have been found
to be mutated or overexpressed in more than 30% of hu-
man tumors (Bos, 1989).
Ras-induced tumorigenesis is accompanied by a num-
ber of biochemical changes, including the activation of the
ERK MAP kinase (MAPK)-, PI3K-, and RalGDS-signaling
pathways (Downward, 2003). Furthermore, increased in-
tracellular levels of reactive oxygen species (ROS) have
also been reported to mediate some biological effects of
oncogenic H-Ras, such as mitogenesis in fibroblasts (Irani
et al., 1997), the onset of premature senescence in primary
cells (Lee et al., 1999; Nicke et al., 2005), the generation of
genomic instability (Woo and Poon, 2004), and malignant
transformation (Mitsushita et al., 2004). In contrast, N-Ras
has not been linked to oxidative stress yet, whereas K-RasCahas been reported to either increase or decrease intracel-
lular ROS levels depending on the cellular context (Maciag
and Anderson, 2005; Santillo et al., 2001). The ability of
other oncogenes, apart from Ras, to induce ROS produc-
tion has not been described; however, BCR/ABL (Sattler
et al., 2000) and several growth factor receptors that sig-
nal through Ras, such as the transforming growth factor-
b (TGF-b) and platelet-derived growth factor (PDGF) re-
ceptors, have all been reported to raise intracellular ROS
levels in hematopoietic cells (Sattler et al., 1999).
Oxidative stress has been traditionally considered as
a toxic by-product of cellular metabolism, but it has
been recently appreciated that ROS are actively involved
in the regulation of signal-transduction pathways (Han-
cock et al., 2001), and that they can also cooperate with
oncogenic signaling in cellular transformation and cancer
(Suh et al., 1999; Woo and Poon, 2004). The carcinogenic
effects of ROS accumulation have been proposed to oper-
ate at various levels, including changes in gene expression
(Allen and Tresini, 2000), increased proliferation and DNA-
mutational rates (Irani et al., 1997; Toyokuni, 2006), andSIGNIFICANCE
The characterization of tumor suppressors whose activity could be stimulated for cancer therapy is an area of in-
tense research. We show that the ability of p38 MAPK to induce apoptosis in response to the detection of reactive
oxygen species (ROS) plays an important inhibitory role in tumor initiation. This activity is likely to be relevant for
human cancer, as the tumorigenicity of cancer cell lines correlates with increased levels of glutathione S-transfer-
ase (GST) proteins that specifically desensitize p38a activation from ROS accumulation. Our results illustrate
a mechanism used by cancer cells for the inactivation of tumor-suppressor pathways and suggest that restoring
the ROS-induced activation of p38 MAPK, for example by targeting GST proteins, may be of potential therapeutic
interest.ncer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc. 191
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high levels of ROS have been detected in several human
cancer cell lines (Szatrowski and Nathan, 1991), as well
as in human tumors from different tissues (Toyokuni
et al., 1995). ROS have also been implicated in the prolif-
eration of melanoma, breast carcinoma, and fibrosarcoma
human tumor cell lines (Church et al., 1993; Fernandez-Pol
et al., 1982). Taken together, these reports support the
causal link between oxidative stress and cancer, which
was proposed 20 years ago (Ames, 1983).
p38a MAPK plays an important role in the coordination
of the cellular responses to many stress stimuli. The sig-
naling pathways leading to the activation of p38a involve
several upstream MAP3Ks, with apoptosis signal-regulat-
ing kinase 1 (ASK1) (MAP3K5) playing a major role in p38a
activation by oxidative stress (Tobiume et al., 2001). ASK1
activation is thought to involve both oligomerization and
autophosphorylation, which is prevented in nonstressed
cells by the binding of stress-sensitive proteins. Two of
these ASK1-binding proteins are thioredoxin (Trx) and glu-
tathione S-transferase Mu-1 (Gstm1), which dissociate
from ASK1 after oxidative stress and heat shock, respec-
tively (Dorion et al., 2002; Matsukawa et al., 2004). Inter-
estingly, overexpression of Gstm1 inhibits p38a activation
by oxidative stress, which might be accounted for by the
binding of both Gstm1 and Trx to the same N-terminal re-
gion of ASK1 (Cho et al., 2001).
In addition to its key role as a coordinator of the cellular
responses to stress, p38a has also been shown to regulate
other cellular processes in a cell-type-specific manner
(Nebreda and Porras, 2000). Of note, p38a negatively reg-
ulates the malignant transformation induced by oncogenic
H-Ras, and several mechanisms have been proposed to
explain this putative tumor-suppressor role, including
inhibition of the ERK pathway (Li et al., 2003), induction
of premature senescence (Wang et al., 2002) or of a p53-
dependent cell cycle arrest (Bulavin et al., 2002), and upre-
gulation of cell cycle inhibitors, such as p16INK4a (Bulavin
et al., 2004) and p21Cip1 (Nicke et al., 2005). Other reports
indicate that p38amay also antagonize malignant transfor-
mation induced by N-Ras in fibroblasts (Wolfman et al.,
2002) and by K-Ras in colon cancer cells (Qi et al., 2004),
although the mechanisms involved are poorly understood.
Here, we show that p38a is not a general inhibitor of on-
cogenic signaling, but that it specifically modulates malig-
nant transformation induced by oncogenes that produce
ROS. Interestingly, some human cancer cells can by-
pass the inhibitory role of p38a on ROS accumulation,
and this leads to enhanced tumorigenicity. Thus, oxidative
stress sensing by p38a MAPK is an important mechanism
by which to negatively regulate the onset of cancer.
RESULTS
p38a-Deficient MEFs Are Sensitized
to H-RasV12-Induced Transformation
To investigate the effect of p38a on H-Ras-induced trans-
formation, fibroblasts derived from wild-type (WT) and
p38a/ mouse embryos were immortalized by the 3T3192 Cancer Cell 11, 191–205, February 2007 ª2007 Elsevier Incprotocol. Consistent with previous reports (Brancho
et al., 2003; Chen et al., 2000; Faust et al., 2005), we found
that immortalized WT and p38a/ mouse embryo fibro-
blasts (MEFs) proliferated with comparable rates, al-
though upon H-RasV12 transduction (Figure 1A) or under
low-serum conditions (Figure S1; see the Supplemental
Data available with this article online), p38a/ MEFs pro-
liferated faster than WT MEFs. This was consistent with
higher levels of cyclin D1 in exponentially proliferating
p38a/ MEFs expressing H-RasV12 (Figure 1B), as ex-
pected from the known ability of p38a to downregulate cy-
clin D1 expression (Lavoie et al., 1996). However, in con-
trast to the described role of p38a as a modulator of the
p16Ink4a/p19Arf pathways in primary stem cells and breast
tumorigenesis (Bulavin et al., 2004; Ito et al., 2006), we
observed no differences in the levels of p16Ink4a between
H-RasV12-expressing WT and p38a/ MEFs (Figure 1C),
whereas p19Arf was not detected by immunoblotting (data
not shown).
We also analyzed the ability of p38a-deficient cells to
grow in soft agar, which is considered a better marker for
in vivo tumorigenesis than the rates of proliferation. We
found that H-RasV12-expressing p38a/ MEFs were
40% less adherent (data not shown) and showed a more
refringent morphology than H-RasV12-transduced WT
MEFs (Figure 1D). Moreover, H-RasV12-transformed
p38a/ MEFs formed bigger foci and were able to
produce about 9-fold more colonies in soft agar than
H-RasV12-transduced WT MEFs (Figures 1E and 1F). Im-
portantly, the differences between WT and p38a/ MEFs
could be rescued by reintroduction of p38a in H-RasV12-
expressing p38a/ cells (Figures 1G and 1H), arguing
that the observed differences are directly due to the ab-
sence of p38a, and not to secondary genetic alterations.
Of note, we could not detect p53 protein expression in im-
mortalized p38a/ and WT MEFs, either when proliferat-
ing or after stress treatments (Figure 1B and data not
shown), suggesting that p38a inhibits H-RasV12-induced
transformation of fibroblasts by p53-independent mecha-
nisms, in agreement with previous work (Bulavin et al.,
2004). The in vivo relevance of these observations was
confirmed by injecting nude mice subcutaneously with
H-RasV12-transformed p38a/ MEFs, which gave rise
to tumors significantly faster than H-RasV12-transformed
WT MEFs (Figure 1I).
Sustained Activation of p38a Inhibits H-RasV12-
Induced Transformation, but Not ERK Activation
NIH3T3 fibroblasts are immortalized, highly contact-
inhibited cells that carry a homozygous deletion in the en-
tire INK4a/ARF locus. To confirm whether p38a could
negatively regulate H-RasV12-induced transformation in-
dependently of p16INK4a and p19ARF, NIH3T3 fibroblasts
were transfected with H-RasV12, either alone or together
with the specific p38 MAPK activator MKK6DD. Expres-
sion of MKK6DD resulted in efficient activation of endog-
enous p38a (Figure 2A), which correlated with the inhibi-
tion of H-RasV12-induced transformation, as determined
by the less refringent morphology and the reduced.
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ROS-Mediated Antioncogenic Effect of p38aFigure 1. p38a Negatively Regulates H-RasV12-Induced Malignant Transformation
(A) Proliferation rates of H-RasV12-expressing WT and p38a/ MEFs. The arrow indicates when H-RasV12-expressing p38a/ cells achieved con-
fluency. The error bars show SD.
(B and C) Total cell lysates from exponentially proliferating WT and p38a/ MEFs (50 mg total protein) were analyzed by immublotting with the in-
dicated antibodies. Primary and SV40 LT-Ag-immortalized MEFs were used as controls for p53 and p16INK4a immunoblotting, respectively (indicated
by asterisks).
(D–F) H-RasV12-expressing WT and p38a/ MEFs as well as control cells transduced with the empty vector were selected with puromycin
(1.5 mg/ml) for 1 week and then compared in terms of (D) morphology, (E) ability to form foci, and (F) anchorage-independent growth in soft agar.
(G and H) p38a/ MEFs were rescued by forced expression of p38a and then analyzed for (G) anchorage-independent growth and morphology, as
well as by (H) immublotting with the indicated antibodies.
(I) Immunodeficient nude mice were injected subcutaneously with control p38a/ (rhombus) and H-RasV12-expressing WT (triangles) or p38a/
(squares) MEFs, and tumor size was measured periodically. Error bars show SD.number of both foci formation and anchorage-indepen-
dent growth (Figure 2B).
The ability of p38 MAPK to inhibit ERK activation has
been previously documented (Li et al., 2003). We therefore
investigated whether the negative effect of p38a on H-
RasV12-induced transformation could be accounted for
by interfering with the activation of the ERK pathway,
since this has been shown to be important for the H-Ras-Cainduced transformation of mouse fibroblasts (Cowley
et al., 1994; Mansour et al., 1994). We found that exponen-
tially proliferating H-RasV12-WT MEFs contained similar
phospho-ERK levels as H-RasV12-p38a/ cells (Fig-
ure 1B). Moreover, kinetic analysis of ERK activation in
response to serum stimulation showed no differences be-
tween p38a/ and WT MEFs, either in the presence or
absence of H-RasV12 expression (Figure 2C). We alsoncer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc. 193
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ROS-Mediated Antioncogenic Effect of p38aFigure 2. p38a Regulates H-RasV12-Induced Transformation Independently of the INK4a/ARF Locus and the ERK Pathway
(A) NIH3T3 fibroblasts were transfected with H-RasV12 in combination with MKK6DD or an empty vector and 48 hr later were analyzed by immuno-
blotting with the indicated antibodies.
(B) NIH3T3 cells stably expressing H-RasV12 alone or in combination with MKK6DD were analyzed for transformation-associated morphological
changes (left panels) and anchorage-independent growth in soft agar (middle panels). NIH3T3 cells were also transiently transfected with H-
RasV12 or H-RasV12 plus MKK6DD and were analyzed for foci formation during the course of 3 weeks (right panels).
(C) Kinetics of ERK activation in the indicated cell lines after incubation in 0.5% serum for 60 hr, followed by stimulation with 10% FBS.
(D) NIH3T3 cells were transiently transfected with the indicated oncogenes, together with MKK6DD or an empty vector, and 48 hr later were analyzed
by immunoblotting.confirmed that MKK6DD expression affected neither the
basal nor the oncogene-induced levels of active ERK in
NIH3T3 fibroblasts (Figure 2D). These results indicated
that p38a was not inhibiting H-RasV12-induced transfor-
mation of MEFs and NIH3T3 cells by interfering with
ERK activation.
p38a Inhibits H-RasV12-Induced ROS Accumulation
by Triggering Apoptosis
Our results indicated that p38a was able to inhibit
H-RasV12-induced transformation of premalignant fibro-194 Cancer Cell 11, 191–205, February 2007 ª2007 Elsevier Iblasts independently of both p53 and the INK4a/ARF lo-
cus, and without interfering with ERK activation. Next,
we investigated the effect of p38a on the production of
ROS, a well-known biological consequence of oncogenic
H-Ras expression (Irani et al., 1997).
We found that H-RasV12-p38a/ MEFs accumulated
significantly higher levels of intracellular ROS than H-
RasV12-WT MEFs (Figure 3A). Quantitative analysis
showed that H-RasV12-WT MEFs contained 2- to 3-fold
higher ROS levels than nontransformed WT or p38a/
cells, whereas ROS levels detected in p38a/ MEFsnc.
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Interestingly, the higher levels of ROS in H-RasV12-
p38a/ MEFs not only correlated with their enhanced
transformed phenotype, but also with two known out-
comes of oxidative stress, which are reduced intracellular
phosphatase activity and high levels of genomic instability
(Figures S3A and S3B). In support of the idea that high
intracellular ROS levels could play a causal role in the
malignant phenotype, we were able to inhibit the more
dramatic transformed morphology of H-RasV12-express-
ing p38a/ MEFs by incubation with the antioxidant glu-
tathione (Figure 3B).
To further analyze the interplay between p38a, ROS ac-
cumulation, and H-RasV12-induced transformation, we
used a 4-hydroxytamoxifen (OHT)-inducible ER-HRasV12
system (De Vita et al., 2005). Surprisingly, we found that,
early in H-RasV12 induction with OHT, both p38a/ and
WT MEFs contained comparable ROS levels (Figure 3C,
upper panel). However, long-term accumulation of ROS
was only observed in p38a/ cells. In order to elucidate
why WT cells were not able to accumulate ROS, we
monitored the time-dependent appearance of the ER-
HRasV12-induced transformed morphology in WT and
p38a/ MEFs (Figure 3C, lower panel). We observed
that both WT and p38a/ MEFs acquired a similar trans-
formed morphology shortly after OHT treatment. How-
ever, WT cells undergo up to 10-fold more apoptosis
than p38a/ cells when treated with OHT for 1 week
(Figure 3C, arrows, and Figure 3D), which occurs in paral-
lel with a drop in their ROS levels between 7 and 10 days
after OHT treatment, depending on the experiment. The
occurrence of apoptosis was confirmed biochemically
by the accumulation of processed p85 PARP (Figure 3E),
and its key role for ROS downregulation in WT MEFs
was further supported by incubation with the pan-caspase
inhibitor ZVAD-fmk. Indeed, the inhibition of apoptosis by
ZVAD-fmk (Figure 3F) interfered with ROS downregulation
in WT MEFs at late times after ER-HRasV12-induction,
without affecting ROS levels in p38a/ cells (Figure S4).
Extended treatment with OHT for up to 3 weeks did not
have any further effect on the surviving cells, which
showed sustained low levels of ROS. Moreover, no apo-
ptotic crisis was observed in p38a/ MEFs expressing
ER-HRasV12 or in control WT and p38a/ MEFs treated
with OHT, arguing in favor of an early p38a-mediated
inhibitory mechanism in response to oncogenic H-
RasV12-induced ROS. In agreement with this, phospho-
p38a levels transiently increased after OHT treatment, in
parallel with p85 PARP accumulation (Figure 3E), and de-
creased after 2 weeks of treatment.
Next, we studied whether the observed increase in
p38a activity was necessary for H-RasV12-induced apo-
ptosis. WT MEFs expressing ER-HRasV12 were incu-
bated with the p38 MAPK inhibitor SB203580, and apo-
ptosis was quantified 8 days after OHT treatment. As
expected, SB203580 strongly impaired the H-RasV12-
induced activation of the p38 MAPK pathway and the sub-
sequent apoptotic response (Figure 3F), without affecting
the H-RasV12-induced accumulation of ROS (data notCshown), which indicates that p38a activation lays down-
stream of ROS and is required for apoptosis induction
by H-RasV12.
H-RasV12-Induced ROS Accumulation Is Mediated
by the ERK and Rac1 Pathways and Involves
NADPH Oxidases
To elucidate which pathways mediate the long-term accu-
mulation of ROS in H-RasV12-transformed p38a/
MEFs, we used rotenone, an inhibitor of the mitochondrial
electron transport chain, and diphenylene iodonium chlo-
ride (DPI), an inhibitor of NADPH oxidase (NOX) enzymes
that are major mediators of the nonmitochondrial ROS
production (Kamata and Hirata, 1999). Incubation with ro-
tenone did not affect H-RasV12-induced ROS accumula-
tion in p38a/ MEFs, whereas DPI basically abolished it
(Figure S5A). Nox genes have been previously associated
with cellular transformation and cancer (Suh et al., 1999).
In agreement with this, we found that the Nox1 and Nox4
mRNAs were upregulated in H-RasV12-transformed
p38a/ MEFs, suggesting that these two NOX family
members may be involved in H-RasV12-induced ROS
production in fibroblasts (Figure S5B).
We also used chemical inhibitors to investigate the con-
tribution of different Ras-activated signaling pathways to
ROS production. Our results indicated that H-RasV12-
induced ROS accumulation in p38a/ MEFs was medi-
ated by cooperative action of the ERK and Rac1 pathways,
but did not require PI3K activity (Figures S5C and S5D).
Uncoupling p38a Activation from Oxidative Stress
Enhances H-RasV12-Induced Transformation
We have recently identified gstm2 as one of the genes that
may be regulated by p38a in H-RasV12-transformed
MEFs (unpublished data). Gstm2 was more than 90% ho-
mologous to Gstm1 (Figure 4A), another member of the
same GST family whose overexpression has been re-
ported to inhibit the oxidative stress-induced activation
of p38 MAPK by binding to and inhibiting ASK1 (Cho
et al., 2001; Dorion et al., 2002). gstm1 has been associ-
ated with elevated breast cancer risk (Parl, 2005) and is
also overexpressed in tumors from brain, skin, and kidney,
according to the Cancer Genome Anatomy Project data-
base (http://cgap.nci.nih.gov/Tissues). To address the pu-
tative role of Gstm2 as a modulator of p38a function in H-
RasV12-induced tumorigenesis, we investigated whether
Gstm2 overexpression could affect the activation of
p38a by H-RasV12. In agreement with a recent report de-
tailing the use of ovarian epithelial cells (Nicke et al., 2005),
we found that the H-RasV12-induced activation of p38a
was impaired in the presence of the antioxidant N-ace-
tyl-L-cysteine (NAC), suggesting that ROS are also key
mediators of the activation of p38a by H-RasV12 in fibro-
blasts. Interestingly, Gstm2 overexpression inhibited the
activation of p38a (and its activator MKK6) by H-
RasV12, but interfered neither with the activation of other
H-Ras-regulated signaling pathways, such as the PI3K/
Akt pathway, nor with the activation of p38a by other stim-
uli such as UV (Figure 4B). This result argues that Gstm2ancer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc. 195
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ROS-Mediated Antioncogenic Effect of p38aFigure 3. p38a Prevents the Long-Term Accumulation of H-RasV12-Induced High Levels of ROS through an Apoptotic Response
(A) WT and p38a/ MEFs stably expressing H-RasV12 were analyzed for intracellular ROS levels by immunofluorescence.
(B) WT and p38a/ MEFs were transduced with H-RasV12 and then selected for 1 week with either 1 mg/ml puromycin alone (top panels) or in com-
bination with reduced glutathione (10 mM for 3 days, followed by 5 mM for 4 days; bottom panels) before the pictures were taken.
(C) WT and p38a/ MEFs expressing an OHT-inducible H-RasV12 construct (ER-HRasV12) were treated for different times with 1 mM OHT, and ROS
accumulation was visualized by immunofluorescence (top panel). Transformation-associated morphological alterations were also monitored in par-
allel (bottom panel). The insets show magnifications of representative fields.196 Cancer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc.
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RasV12-induced ROS accumulation. We confirmed that
Gstm2 can also interact with ASK1 (Figure 4C), which
probably accounts for its ability to inhibit ROS-induced
p38 MAPK activation, as it has been proposed for
Gstm1 (Cho et al., 2001). Consistent with the ability of
Gstm2 to interfere with p38a activation, we detected
long-term ROS accumulation in H-RasV12-WT MEFs ex-
pressing Gstm2 (Figure 4D). Most importantly, accumula-
tion of ROS in H-RasV12-WT MEFs after Gstm2 over-
expression correlated with a stronger transformed
phenotype, similar to that observed in H-RasV12-p38a/
MEFs, both at the morphological level and by the en-
hanced ability of the cells to grow in soft agar (Figure 4E).
Of note, the growth of H-RasV12-p38a/ MEFs in soft
agar was not affected by Gstm2 overexpression (data
not shown), suggesting that p38a was an important target
for the Gstm2 effect observed in WT cells. These results
strongly support the hypothesis that p38a functions as
a key oxidative stress sensor in oncogenic transformation
by H-RasV12.
p38a Specifically Regulates Malignant
Transformation by ROS-Inducing Oncogenes
We next investigated whether the role of p38a as a ROS
sensor in H-RasV12- induced transformation could be ex-
tended to other oncogenes. Thus, WT and p38a/ MEFs
were transduced with a panel of oncogenes, covering dif-
ferent pathways and subcellular localizations, and were
analyzed in terms of anchorage-independent growth, fo-
cus formation, and intracellular ROS levels (Table 1). As
with H-RasV12, none of the oncogenes tested were able
to induce long-term accumulation of ROS in WT MEFs.
However, the oncogenes Neu V664E and N-RasV12 did
induce high ROS levels in p38a/ MEFs that were com-
parable to those observed for H-RasV12 (Table 1). Inter-
estingly, ROS accumulation in p38a/ MEFs expressing
N-RasV12 or Neu V664E correlated with a more dramatic
transformed phenotype in these cells than in WT MEFs ex-
pressing the same oncogenes. No differences in soft agar
growth were observed between WT and p38a/ MEFs
with the other oncogenes, including K-RasV12, which
was consistent with their inability to induce long-term ac-
cumulation of high ROS levels in MEFs (Table 1). These re-
sults suggest that p38a functions as an oxidative stress
sensor in tumorigenesis, with the capacity to downregu-
late malignant transformation by oncogenes that induce
ROS production. Of note, p38a negatively regulated the
induction of focus formation by oncogenic forms of Raf-
1, B-Raf, and K-Ras, which do not produce high ROS
levels (Table 1), suggesting that p38a may also have
ROS-independent antioncogenic functions.CanGstm2 Impairs p38a Activation by Oxidative Stress
in Human Epithelial Cells
Gstm2 was able to specifically inhibit p38a activation after
oncogene-induced oxidative stress, without affecting
other H-Ras-activated pathways in murine fibroblasts
(Figure 4B). To complement these observations, we over-
expressed Myc-tagged Gstm2 in HEK293 human epithe-
lial cells, which then were stimulated with H2O2, sorbitol,
UV irradiation, and cisplatin, or cotransfected with H-
RasV12. We confirmed that Gstm2 efficiently inhibited
p38a activation induced by H-RasV12 or H2O2 (Figures
S6A and S6B). However, the Gstm2 inhibitory effect was
more modest in the cases of osmotic shock, UV irradia-
tion, and cisplatin treatment (Figure S6C). On the other
hand, Gstm2 overexpression did not affect ERK activation
by any of these stimuli and either only partially inhibited or
had no effect on JNK activation induced by H2O2 and H-
RasV12, respectively (data not shown). These results indi-
cate that Gstm2 targets a key regulator of the oxidative
stress-induced activation of p38 MAPK (i.e., ASK1),
whereas additional pathways may contribute to JNK acti-
vation by oxidative stress.
ROS Accumulation in Human Cancer Cell Lines
Correlates with Enhanced Tumorigenicity
Our results indicated that oncogene-induced ROS accu-
mulation correlated with enhanced tumorigenicity in fibro-
blasts. However, many human neoplasms originate from
epithelial cells, in which little is known about ROS levels.
Thus, we compared intracellular ROS levels and tumori-
genic potential in a panel of human epithelial cell lines de-
rived from colon, prostate, breast, and lung tumors. We
observed a strong correlation in all tissues between high
levels of ROS and efficient anchorage-independent
growth (Figure 5). These results suggest that ROS accu-
mulation may enhance the malignant phenotype of cancer
cells, in agreement with the procarcinogenic effects medi-
ated by oxidative stress. In contrast, we observed no cor-
relation between oxidative stress accumulation and the
invasivity of these cancer cell lines (Figure 5). This was
confirmed by the lack of effect of antioxidant treatment
on the invasivity of MDA-MB-231 cells (data not shown).
Thus, intracellular ROS levels seem to correlate with the
tumorigenic potential of human cancer cells, but not with
their invasive capacity.
Cancer Cell Lines with High ROS Levels Are Partially
Impaired in p38a Activation
The identification of cancer cell lines that contained high
levels of ROS despite expressing normal levels of p38a
(Figure 6A) was intriguing, given the ability of p38a to
sense oxidative stress and negatively regulate ROS(D) Apoptosis was determined in empty vector- and ER-HRasV12-transduced WT and p38a/ MEFs after 8 days of treatment with 1 mM OHT. Error
bars show SD.
(E) ER-HRasV12-expressing WT MEFS were treated with 1 mM OHT and analyzed by immunoblotting with the indicated antibodies.
(F) ER-HRasV12-expressing WT MEFs were treated with 1 mM OHT for 4 days and then incubated for another 4 days with OHT together with
SB203580 (10 mM) or ZVAD-fmk (20 mM). Cell lysates were analyzed by immunoblotting with the indicated antibodies. Apoptosis was quantified
by an ELISA assay (right panel). Error bars show SD.cer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc. 197
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ROS-Mediated Antioncogenic Effect of p38aFigure 4. Uncoupling ROS Accumulation from p38a Activation Results in Enhanced Tumorigenicity
(A) Amino acid sequence alignment of murine Gstm1 (NP_034488) and Gstm2 (NP_032209). Asterisks indicate identical amino acids.
(B) ER-HRasV12-expressing WT MEFs were transduced with murine Gstm2 or an empty vector and then either stimulated with UV irradiation or
treated with 1 mM OHT for 5 days. One sample was coincubated with 5 mM NAC during the last 16 hr of OHT treatment. Total cell lysates were an-
alyzed by immunoblotting with the indicated antibodies.
(C) Lysates from 293T cells transfected with plasmids expressing ASK1-HA and Myc-Gstm2 were subjected to immunoprecipitation with Myc anti-
body. The total lysates and the Myc immunoprecipitates were analyzed by immunoblotting with the indicated antibodies.198 Cancer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc.
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ROS-Mediated Antioncogenic Effect of p38aTable 1. Effect of p38a on Anchorage-Independent Growth and Focus Formation Induced by Different Oncogenes
in Mouse Fibroblasts
Oncogene ROSa (p38a/ MEFs)
Soft Agarb
(p38a/ MEFs)
Focus Formation
p38a/ MEFsc NIH3T3 + MKK6DDd
Neu V664E + Enhanced Enhanced Reduced
H-RasV12 + Enhanced Enhanced Reduced
N-RasV12 + Enhanced Enhanced Reduced
K-RasV12  As WT Enhanced ND
B-Raf V599E  As WT Enhanced Reduced
Raf-1 22W  As WT Enhanced Reduced
RalGDS-CAAX  As WT As WT ND
Rac1 N115I  As WT As WT ND
MEK1 DN  As WT As WT As NIH3T3
v-Mos  As WT As WT ND
c-Src Y527F  As WT As WT As NIH3T3
SV40 LT-Ag  As WT As WT As NIH3T3
v-Jun  As WT As WT As NIH3T3
c-Myc  As WT As WT As NIH3T3
a ROS levels were visualized by immunofluorescence; ‘‘+’’ indicates ROS accumulation to high levels.
b Soft agar was used to measure anchorage-independent growth in p38a/ MEFs as compared to WT MEFs.
c Focus formation in p38a/ MEFs as compared to WT MEFs.
d Focus formation in NIH3T3 fibroblasts expressing the p38 MAPK activator MKK6DD versus NIH3T3 fibroblasts. ND, not deter-
mined.accumulation. Thus, we investigated the pattern of p38a
activation in response to H2O2-induced oxidative stress
in colon and breast cancer cell lines, which contained var-
ious levels of ROS. As shown in Figures 6A and 6B, H2O2
treatment activated p38a about 2-fold more efficiently in
ROS-negative than in ROS-positive cancer cells. Interest-
ingly, no differences in the activation of p38a were ob-
served when cells were exposed to other stresses such
as UV irradiation and osmotic shock (Figure 6C) or cis-
platin treatment (data not shown). Our results therefore in-
dicate that cancer cell lines with high ROS levels have de-
veloped specific mechanisms by which to desensitize
p38a activation from oxidative stress, most likely in order
to tolerate the high levels of ROS. Of note, whereas p38a
activation was partially uncoupled from oxidative stress in
ROS-producing cancer cells, JNKs, particularly the p54
JNK isoform, appeared to be more efficiently activated
(Figure 6B). On the other hand, the ERK pathway was sim-
ilarly activated in ROS-positive and ROS-negative cancer
cell lines (Figure 6B).
As mentioned above, Gstm1 has been reported to in-
hibit the activation of p38 MAPK by oxidative stress,
a function that we have shown is also shared by Gstm2.CaInterestingly, Gstm1 mRNA and protein levels were very
high in most ROS-positive cancer cell lines, while they
were absent or expressed at very low levels in ROS-
negative cells (Figure 7A).
Next, we analyzed whether higher expression levels
of Gstm proteins could account for the differences in
ROS accumulation and p38a activation observed in
cancer cell lines. First, we found that p38a activation
was enhanced by siRNA-mediated knockdown of
Gstm1 in the ROS-producing cancer cell lines MDA-
MB-231 and A549 (Figure 7B) as well as in DU145
(data not shown). Similar results were obtained upon
knockdown of Gstm2 in the cancer cell lines MCF7
(Figure 7B) and SW620 (data not shown), which express
Gstm2, but not Gstm1 (Figure 7A and Figure S7). Interest-
ingly, the activation of p38a observed upon knockdown of
Gstm1 and Gstm2 correlated in all cases with enhanced
apoptosis (Figure 7B). Conversely, overexpression of
Gstm2 in MCF7 and SW620 cells resulted in reduced
basal levels of activated p38a, as well as in the desensiti-
zation of p38a to oxidative stress (Figure 7C). Finally, over-
expression of Gstm2 led to the accumulation of higher
levels of ROS and the acquisition of a more malignant(D and E) ER-HRasV12-expressing WT MEFs were transduced with murine Gstm2 or an empty vector, treated with 1 mM OHT for 3 weeks, and
then analyzed for (D) intracellular ROS levels and (E) transformation-associated morphological alterations and anchorage-independent growth in
soft agar.ncer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc. 199
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ROS-Mediated Antioncogenic Effect of p38aFigure 5. High Levels of ROS Correlate
with Enhanced Tumorigenicity, but Not
Invasivity, in Human Cancer Cell Lines
from Different Tissues
The indicated human cancer cell lines were
analyzed for intracellular ROS levels by immu-
nofluorescence, for anchorage-independent
growth in soft agar (+, 2,000–4,000; ++,
5,000–7,000; +++, 10,000–17,000 colonies),
and for invasivity in matrigel chambers
(, <15; +, 25–50; ++, >90 arbitrary units).
ND, not determined.phenotype in MCF7 cells (Figure 7D), as well as in
SW620 cells (data not shown). Of note, we did not
observe changes in ROS levels after Gstm downregulation
in the cancer cell lines mentioned above (data not
shown), suggesting that Gstm proteins function down-
stream of ROS.
Taken together, these results argue that upregulation of
Gstm proteins may be responsible for the partially
impaired activation of p38a in ROS-producing cancer
cells. Thus, Gstm1 and Gstm2 may inhibit the ROS-
sensing and tumor-suppressor function of p38a in
human epithelial cells, which is in agreement with their
association with increased malignancy of several types
of cancer.
DISCUSSION
p38aMAPK was identified as a protein kinase that coordi-
nates the cellular responses to many types of stresses, in-
cluding those that trigger oxidative stress production. In
addition, p38a has been recently shown to mediate phys-
iological processes in response to endogenous ROS,
such as the regulation of the lifespan of murine hemato-
poietic stem cells (Ito et al., 2006). Here, we show that
the ability of p38a to trigger apoptosis in response to
oncogene-induced ROS accumulation plays a key role in
the regulation of malignant transformation. Interestingly,
highly tumorigenic human cancer cells can override this
p38a function.200 Cancer Cell 11, 191–205, February 2007 ª2007 Elsevier Incp38a as a Negative Regulator of Malignant
Transformation
Previous studies have established p38a as a negative reg-
ulator of H-RasV12-induced cellular transformation, an ef-
fect that can be mediated by p53 and the p16INK4a and
p19ARF pathways (Bulavin et al., 2002, 2004). Our results
indicate that p38a can also inhibit H-RasV12-induced tu-
morigenesis in the absence of a functional p53 response
and independently of p16INK4a/p19ARF. It therefore ap-
pears that the mechanisms by which p38a can impinge
on malignant transformation may vary depending on the
cell type and, probably, also between primary and immor-
talized cells (Ito et al., 2006; Li et al., 2003).
We show here that the ability of p38a to detect oxidative
stress production early in the process of oncogenic H-
Ras-induced transformation is important for its inhibitory
effect on tumorigenesis. We have also extended this
p38a-mediated inhibitory mechanism to other onco-
genes, providing a molecular basis for the specificity of
p38a as a tumor suppressor. Namely, we found that p38a
functions as a tumor surveillance system activated by
ROS, which, in turn, inhibits tumor initiation, at least in part,
by inducing apoptosis. In agreement with this, ROS-
induced sustained activation of p38a has been implicated
in apoptosis induction (Tobiume et al., 2001), which can be
mediated by both transcriptional and posttranscriptional
mechanisms (Porras et al., 2004; Wada and Penninger,
2004), although low levels of oxidative stress can also in-
duce a p38 MAPK-dependent cell cycle arrest (Kurata,
2000). Oxidative stress sensing, therefore, represents a.
Cancer Cell
ROS-Mediated Antioncogenic Effect of p38amajor mechanism for the inhibitory effect of p38a on
oncogene-induced transformation.
Mechanisms of p38a Activation
by Oncogene-Induced ROS
Several oncogenes have been reported to induce ROS ac-
cumulation and to rely on high ROS levels for efficient
transformation (Mitsushita et al., 2004), but the molecular
links between oncogene activation and ROS production
are not completely understood. We found that oncogenic
H-Ras-induced accumulation of ROS in p38a/ cells re-
quires NOX activity and is blocked by the combined use of
ERK and Rac1 inhibitors. This is consistent with previous
work showing that ERK can induce transcriptional upregu-
lation of Nox1 (Mitsushita et al., 2004), whereas Rac1
Figure 6. Human Cancer Cell Lines with High ROS Levels Are
Partially Impaired in p38a Activation
(A) Cell lines derived from human colon and breast tumors, which con-
tained either low or high ROS levels, were exposed to 1 mM H2O2 for
30 min and analyzed by immunoblotting with the indicated antibodies.
(B) ROS-negative SW620 and ROS-positive RKO colon cancer cells
were treated with 5 mM H2O2 for different times and analyzed by im-
munoblotting with the indicated antibodies.
(C) ROS-negative (HT-29, SW620, MCF7) and ROS-positive (RKO,
SKBR-3) cancer cell lines were exposed either to UV irradiation or
osmotic shock, and phospho-p38 levels were analyzed by immuno-
blotting.Cacooperates in the assembly of the fully active NOX com-
plex at the plasma membrane (Hancock et al., 2001).
Our results are in agreement with recent work showing
that activation of p38a in response to oncogenic H-Ras re-
quires ROS production (Nicke et al., 2005). Furthermore,
the slow kinetics of p38a activation, which takes 3–4
days from the onset of oncogenic H-Ras signaling, sug-
gests that p38a is probably activated as a consequence
of the high ROS levels accumulated in the cells, rather
than as a direct target of H-Ras signaling. Then, how do
oncogene-induced ROS lead to p38a activation? One of
the key mediators of ROS-induced p38a activation is
ASK1 (Matsukawa et al., 2004). Thus, it is foreseen that
oncogene-induced ROS would oxidize certain cysteine
residues of Trx and induce its dissociation from ASK1,
hence inducing the activation of the JNK and p38
pathways. Of note, whereas ASK1 is the major mediator
of p38a activation by ROS (Tobiume et al., 2001),
MEKK1 may collaborate with ASK1 for the activation
of JNK by oxidative stress (Xia et al., 2000; Yujiri et al.,
2000).
In addition to the well-characterized role of ASK1 in the
activation of p38a by oxidative stress, a recent report has
also identified the Ste20 family kinase MINK (MAP4K6) as
a novel mediator of the H-RasV12-induced activation of
p38 MAPK (Nicke et al., 2005). The mechanism by which
H-RasV12 activates MINK is unknown but requires both
ERK activation and ROS production. In turn, MINK may
lead to the activation of the p38 MAPK pathway through
both ASK1 and Tpl2. The interplay between the direct ac-
tivation of ASK1 by ROS and the participation of ASK1 in
ROS-induced MINK signaling is unclear, but it might re-
flect different ROS-induced cellular responses dependent
on signal duration or intensity. Thus, whereas ROS-
induced, Trx-dependent activation of ASK1 has normally
been associated with the induction of apoptosis (Tobiume
et al., 2001), the MINK-mediated ASK1 activation by ROS
results in cell cycle arrest (Nicke et al., 2005).
The ROS-p38a Connection in Human Cancer
Suppression of apoptosis is thought to be an important
aspect of tumor development (Evan and Vousden,
2001), and multiple mechanisms for inhibition of apoptosis
have been identified in human tumors. Furthermore, inac-
tivation of apoptotic proteins potentiates malignant trans-
formation in vitro (Kennedy and Davis, 2003). In agreement
with these observations, we show that p38a can inhibit
cell tumorigenicity by triggering oncogene-induced apo-
ptosis mediated by ROS. The relevance of this finding
was confirmed by the observation that human cancer
cell lines have developed a mechanism by which to un-
couple p38a activation from oxidative stress production,
which results in enhanced tumorigenicity. This mecha-
nism relies on the ability of the GST family members
Gstm1 and Gstm2 to impair p38a activation in response
to ROS accumulation (Cho et al., 2001; Dorion et al.,
2002). Indeed, the ability of highly tumorigenic cancer
cell lines to accumulate very high levels of ROS correlates
with the upregulation of Gstm1 and Gstm2. Takenncer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc. 201
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ROS-Mediated Antioncogenic Effect of p38aFigure 7. Gstm1 and Gstm2 Modulate the Activation of p38a by Oxidative Stress in Several Human Cancer Cell Lines
(A) gstm1 (NM_000561) expression was analyzed by both RT-PCR (top panel) and western blot (bottom panel) in several human cancer cell lines.
(B) Downregulation of Gstm1 and Gstm2 by siRNA enhances both p38a activation and the basal apoptotic levels (as indicated by the accumulation in
p85 PARP) of human cancer cell lines. Analysis by qRT-PCR confirmed that treatment with gstm2 siRNA downregulated the gstm2 mRNA levels to
about 40% of those observed in untreated MCF7 cells.
(C) Myc-Gstm2 overexpression in the ROS-negative cancer cell lines MCF7 and SW620 reduces the basal levels of phospho-p38a (left panels) and
impairs the activation of p38a by oxidative stress (right panels).
(D) MCF7 cells stably infected with Myc-Gstm2 or empty vector (EV) were analyzed for intracellular ROS levels (middle panels) and anchorage-
independent growth in soft agar (right panels).together, these results suggest that the p38 MAPK-signal-
ing pathway may suppress tumor formation in vivo by in-
ducing apoptosis. Furthermore, certain members of the202 Cancer Cell 11, 191–205, February 2007 ª2007 Elsevier IncGST family may function as potential oncogenes in human
cancer, by impairing the normal inhibitory responses, such
as apoptosis, triggered by p38a in response to ROS.
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tion between the expression of several GST family mem-
bers and cancer progression has been recently proposed
(Parl, 2005; Townsend and Tew, 2003).
Collectively, our data indicate that cancer cells may
undergo positive selection for high intracellular ROS levels
in their course for proliferative advantages. Thus, the car-
cinogenic effects associated with increased ROS levels
might provide cancer cells with greater plasticity for malig-
nant progression. Interestingly, the associated overex-
pression of Gstm1 and Gstm2 could be a way to specifi-
cally suppress the apoptotic effects of p38a in response
to ROS, without affecting other cellular processes medi-
ated by p38a that might be important for the viability of
the cancer cell. This may explain the lack of evidence for
the loss of p38a expression or activity in human cancer,
and it suggests a new category of tumor-suppressor pro-
teins in which a partial loss of function specifically impairs
their negative contribution to cancer cell survival, while al-
lowing other functions that might be important for malig-
nant progression. This idea is in agreement with evidence
indicating that p38 MAPK might, in some cases, contrib-
ute to cancer progression, for example by mediating can-
cer cell migration (Kim et al., 2003), by activating the tran-
scription factor HIF-1 (Emerling et al., 2005; Nakayama
et al., 2007) or by other mechanisms (Elenitoba-Johnson
et al., 2003; Weijzen et al., 2002). Consistent with this
idea, we have found that inhibition of p38 MAPK impairs
the proliferation and anchorage-independent growth of
some cancer cell lines (data not shown). Thus, whereas
p38a can negatively regulate tumor initiation by triggering
apoptosis in response to oncogene-induced ROS, the
overall effect of p38 MAPK inhibition for human cancer is
likely to be highly dependent on the tumor type and cancer
stage.
EXPERIMENTAL PROCEDURES
Cell Culture
WT and p38a/ primary MEFs were derived from E11.5 and E12.5
embryos (Ambrosino et al., 2003). Cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% heat-inac-
tivated fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin/
streptomycin (all from GIBCO-Invitrogen) and were immortalized by
following the 3T3 protocol. The established cell lines represent pools
of at least 100 independent clones. NIH3T3 mouse fibroblasts were
maintained under subconfluent conditions in DMEM, as described
above; however, in this case, DMEM was supplemented with 10%
heat-inactivated newborn calf serum (NBCS). When used for focus
formation assays, NBCS was reduced to 5%. The HEK293-derived,
virus-packaging cell lines Ampho-Pak and 293T were obtained from
Clontech and M. Serrano (CNIO), respectively. The human cancer
cell lines DU145 and HT-29 were kindly provided by M. Robledo and
J. Bravo (CNIO), respectively. The remaining cancer cell lines were
a kind gift from A. Mun˜oz (Biomedical Research Institute Alberto
Sols, Madrid). All human cancer cell lines were cultured in DMEM
with 10% FBS.
Retroviral Infections
Expression constructs are described in Supplemental Data. Retrovi-
ruses were produced in 293T cells by transient transfection. Culture
supernatants were collected 48 hr (first supernatant) and 72 hr (secondCsupernatant) posttransfection, filtered (0.45 mm filter, PVDF, Millipore),
and supplemented with 4 mg/ml polybrene (Sigma). MEFs at 53 105
cells per 10 cm dish were infected with 6 ml of the first supernatant,
supplemented 24 hr later with 3 ml of the second supernatant, and pu-
rified 48 hr postinfection with either 1–2 mg/ml puromycin for 1 week or
150–200 mg/ml hygromycin for 2 weeks. Pools of at least 105 indepen-
dent clones were normally used. The data for H-RasV12, B-RafV599E,
c-SrcY527F, SV40 LT-Ag, and v-Jun are representative of studies in
which at least three different cell populations that were independently
isolated were used. For other oncogenes, pools were isolated inde-
pendently twice.
For the rescue experiments, two rounds of retroviral infection were
performed as previously described (Ambrosino et al., 2003). MSCV
or MSCV-p38a was first expressed in p38a/ MEFs, followed by
transduction with H-RasV12.
Retroviral transduction of MCF7 and SW620 human cancer cells
with Myc-tagged Gstm2 was performed as described above, except
that 293 Ampho-Pak packaging cells were used instead of 293T cells.
Antibiotic selection was carried out with 100–150 mg/ml hygromycin for
MCF7 and 250–300 mg/ml hygromycin for SW620.
Transformation and Tumorigenicity Assays
NIH3T3-based focus formation assays and anchorage-independent
growth in soft agar were performed by following standard procedures.
Tumorigenicity assays in nude mice were performed in accordance
with institutional guidelines (EMBL Animal Care and Use Committee).
Details are provided in Supplemental Data. For the focus formation as-
says with immortalized MEFs, 9 3 105 WT or p38a/ cells were
seeded per 10 cm plate and were infected with the virus-containing
supernatants from 293 Ampho-Pak cells transfected with oncogene-
encoding retroviral vectors. Cells were maintained in DMEM with
10% FBS, and the medium was changed every 2–3 days. Foci were
counted 10–15 days after transduction.
The in vitro invasion assays were carried out in BD BioCoat Matrigel
chambers (Becton Dickinson) as described in Supplemental Data.
Determination of Intracellular ROS Levels
To visualize intracellular ROS levels, proliferating cells were grown on
coverslips, washed once with warm PBS, and incubated with 10 mM 20-
70-dichlorodihydrofluorescein diacetate (DCF-DA, Molecular Probes
D399) in warm PBS supplemented with 5.5 mM glucose. After
10 min at 37C, PBS was replaced with complete culture medium, and
cells were incubated for an additional 10–15 min, washed once again
with warm PBS, and fixed in 4% formalin (Sigma). Coverslips were in-
cubated with 1 mM 4,6-diamidino-2-phenylindole (DAPI) for nuclei
staining (Sigma) and were mounted in Mowiol (Calbiochem), and intra-
cellular ROS levels were visualized by using an inverted fluorescence
microscope, Leica DM5000B, coupled to a Leica DC500 camera.
Pictures were taken at 633 magnification with the Leica IM50 soft-
ware. Where indicated, cells were pretreated for 12–16 hr with rote-
none (R8875, Sigma), DPI (D2926, Sigma), LY294002 (Calbiochem),
NSC23766 (Calbiochem), or PD98059 (Calbiochem) before ROS
visualization.
For ROS quantification, cells were treated as described above with
10 mM DCF-DA, trypsinized, and analyzed by FACS as described
(Nicke et al., 2005).
Immunoblot Analysis
Cell lysates were prepared as described (Alonso et al., 2000), sepa-
rated by SDS-PAGE, and analyzed by immunoblotting by using the
Odyssey Infrared Imaging System (Li-Cor, Biosciences). Details on
the procedure and antibodies used are described in Supplemental
Data.
Cell Treatments and Assays for Survival and Proliferation
To induce p38 MAPK activation, cells were treated with 1–5 mM H2O2
(Sigma) for 5 min to 5 hr, 0.4 M sorbitol (Sigma) for 6 hr, and 25 mMancer Cell 11, 191–205, February 2007 ª2007 Elsevier Inc. 203
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ROS-Mediated Antioncogenic Effect of p38acisplatin (Sigma) for 8–10 hr or UV stimulated by using a Stratalinker
apparatus, followed by 30 min in the 37C incubator.
Cell proliferation assays were performed by using the MTT cell pro-
liferation Kit I (Roche Diagnostics, Mannheim, Germany). For prolifera-
tion assays with MEFs, 1000 cells/well were seeded in triplicate, and
cell numbers were monitored during the course of 5 days. Experiments
were repeated at least three times.
For apoptosis assays with MEFs expressing the OHT-inducible ER-
HRasV12 construct, 8000 cells/well were seeded in triplicate, and ap-
optosis was measured with the Cell Death Detection ELISAPLUS Kit
(Roche Diagnostics GmbH, Germany). Experiments were performed
twice.
Knockdown of Gstm1 and Gstm2 by siRNA
Human gstm1 and gstm2 as well as control (siGLO) siRNA oligos were
obtained from Dharmacon. MDA-MB-231 and A549 cells were trans-
fected with 200 nM and 150 nM gstm1 siRNA, respectively. MCF7 cells
were transfected with 100 nM gstm2 siRNA. In all cases, DharmaFECT
1 buffer was used (Dharmacon). After 3 days, cells were scraped, and
the lysates were analyzed by immunoblot.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and seven figures and are available at http://www.cancercell.org/cgi/
content/full/11/2/191/DC1/.
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